# Transition Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/transition-bio

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.transitionbio.com
- Total disclosed funding: $44M
- Latest round: Series A (Oct 11, 2024)
- Investors on record: 5

## About

Based in the US, Transition Bio, Inc. specializes in innovative drug discovery, utilizing advanced technologies to identify and optimize therapeutics for complex diseases, particularly in oncology and neurodegenerative conditions.Transition Bio, Inc. operates in the drug discovery sector, focusing on cutting-edge methodologies. The company was founded by Samuel Cohen and has undergone strategic developments to enhance its offerings. Its headquarters is based in Watertown, Massachusetts, US. In its most recent funding round in October 2024, Transition Bio secured USD 13.265 mn in Series A funding from investors including Bristol-Myers Squibb Company and Northpond Ventures, bringing the total raised to USD 13.265 mn with a current valuation of USD 34.922 mn.Transition Bio specializes in an innovative drug discovery platform that integrates droplet microfluidics and advanced cellular imaging technologies to accelerate the identification of novel therapeutics at the molecular level. Their core offerings revolve around a unique end-to-end condensate drug discovery engine that leverages molecular insights to explore the interactions of chemical matter within biological condensate systems. This approach allows for comprehensive analysis and optimization of drug candidates, addressing critical challenges in treating complex diseases, particularly in oncology, neurodegenerative conditions, and inflammation. The technology is designed to serve a diverse client base, including biopharmaceutical companies and research institutions globally, with significant market penetration in North America and Europe, particularly in research hubs such as Cambridge, MA, and Cambridge, UK.Transition Bio generates revenue primarily through strategic partnerships and collaborations with biopharmaceutical firms, research institutions, and other organizations involved in drug discovery. The company enters into agreements that typically involve access to their proprietary technology and data analytics platform, enabling clients to optimize their drug candidates more effectively. Transactions may be structured as collaborative research agreements or subscription-based access to their services, allowing clients to utilize the platform for ongoing projects. Specific pricing structures for their offerings, including flagship products associated with their condensate drug discovery engine, are determined based on the scope of collaboration and services rendered, fostering a tailored approach to meet the unique needs of each client.In October 2024, Transition Bio, Inc. raised USD 13.3 million in Series A funding from returning investors Northpond Ventures, Bristol-Myers Squibb Company, LifeForce Capital, and Taiho Ventures, with new investor Magnetic Ventures joining the round. The company plans to use this funding to further develop its novel platform called Condensomics. Transition Bio aims to expand its reach by targeting new biopharmaceutical markets and enhancing its product offerings, thereby leveraging the latest technological advancements to cater to a broader client base.

## Funding rounds

- Series A, Oct 11, 2024, $13M — Bristol-Myers Squibb Company, Taiho Ventures, LifeForce Capital, Magnetic, Northpond Ventures
- Series A, Mar 24, 2022, $31M — Bristol-Myers Squibb Company, Taiho Ventures, LifeForce Capital, Magnetic, Northpond Ventures
- Seed, Sep 30, 2020 — LifeForce Capital

## Investors

- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Seed, Series A
- Bristol-Myers Squibb Company — Series A
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series A
- Magnetic (https://capitalatlas.ai/funds/magnetic) — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A